KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Gains from Sales and Divestitures: 2019-2024

Historic Gains from Sales and Divestitures for TherapeuticsMD (TXMD) over the last 6 years, with Dec 2024 value amounting to $38,000.

  • TherapeuticsMD's Gains from Sales and Divestitures fell 86.84% to $5,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5,000, marking a year-over-year decrease of 86.84%. This contributed to the annual value of $38,000 for FY2024, which is 78.89% down from last year.
  • TherapeuticsMD's Gains from Sales and Divestitures amounted to $38,000 in FY2024, which was down 78.89% from $180,000 recorded in FY2023.
  • TherapeuticsMD's Gains from Sales and Divestitures' 5-year high stood at $301,000 during FY2020, with a 5-year trough of $327 in FY2022.
  • Its 3-year average for Gains from Sales and Divestitures is $72,776, with a median of $38,000 in 2024.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first plummeted by 99.68% in 2022, then spiked by 54,945.87% in 2023.
  • Over the past 5 years, TherapeuticsMD's Gains from Sales and Divestitures (Yearly) stood at $301,000 in 2020, then tumbled by 65.78% to $103,000 in 2021, then crashed by 99.68% to $327 in 2022, then soared by 54,945.87% to $180,000 in 2023, then crashed by 78.89% to $38,000 in 2024.